Observational studyJournal of translational medicine2024

Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy: a multi-center observational study.

Qing Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.